MedTrace Logo

Maxigesic 325 Acute Dental Pain Study

NCT01420653 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 408

Last updated 2018-12-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether the analgesic effects of Maxigesic USA are greater than acetaminophen, ibuprofen or placebo.

Conditions

  • Dental Pain

Interventions

DRUG

Maxigesic 325

Maxigesic USA (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day with food for 48 hours

DRUG

Acetaminophen

Acetaminophen 325 mg, 3 tablets four times a day, with food for 48 hours

DRUG

Ibuprofen

Ibuprofen 97.5mg, three tablets four times a day, with food for 48 hours.

DRUG

Placebo

placebo, three tablets four times a day, with food for 48 hours

Sponsors & Collaborators

  • AFT Pharmaceuticals, Ltd.

    lead INDUSTRY

Principal Investigators

  • John Currie, Doctor · Clinical Trial New Zealand

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2014-12-31
Completion
2015-01-31

Countries

  • United States
  • New Zealand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01420653 on ClinicalTrials.gov